Status: Not yet recruiting
The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE.
The primary objective of the trial is to evaluate the effect of the addition of belantamab mafodotin to standard of care therapy on the titres of serum anti-dsDNA antibodies in patients with previously treated SLE. Estimand for Primary Endpoint: Change of serum anti-dsDNA antibody titers at 24 weeks of treatment vs baseline.
Participants needed: 12
Trial details
Phase: Phase 2Age: 18-60Biological sex: AllType: InterventionalSponsor: Medical Association for the Study of Cancer Biology and TreatmentUpdated: Sep 28, 2026
Eligibility criteria
Diagnosis of SLE according to the 2019 EULAR/ACR SLE classification criteria. [+20]
Severe kidney (rapidly progressive class III or IV glomerulonephritis) or neurop... [+24]